The DOI matches its Crossref record.
Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation
Abstract
Pathogenic mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant and certain cases of sporadic Parkinson's disease (PD). The G2019S substitution in LRRK2 is the most common genetic determinant of PD identified so far, and maps to a specific region of the kinase domain called the activation segment. Here, we show that autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment. The prominent pathogenic G2019S mutation in LRRK2 results in altered autophosphorylation, and increased autophosphorylation and substrate phosphorylation, through a process that seems to involve reorganization of the activation segment. Our results suggest a molecular mechanistic explanation for how the G2019S mutation enhances the catalytic activity of LRRK2, thereby leading to pathogenicity. These findings have important implications for therapeutic strategies in PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The G2019S mutation in LRRK2 increases its kinase activity in vitro and in vivo.
“the most prominent pathogenic mutation (G2019S) situated within the kinase domain increases its activity in vitro as well as in vivo”
From Distinct Roles for RAB10 and RAB29 in Pathogenic LRRK2-Mediated Endolysosomal Trafficking Alterations (2020) · cites this paper as [8]
Citations
Cited by
Sorted by citations
The role of the LRRK2 gene in Parkinsonism
Li, J.-Q., Tan, L., & Yu, J.-T. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-47 · Cited by 249
Decreased sirtuin deacetylase activity in LRRK2 G2019S iPSC-derived dopaminergic neurons
Schwab, A. J., Sison, S. L., Meade, M. R., Broniowska, K. A., Corbett, J. A., & Ebert, A. D. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.010 · Cited by 80
Rivero-Ríos, P., Romo-Lozano, M., Fernández, B., Fdez, E., & Hilfiker, S. (2020) · Cells · doi:10.3390/cells9071719 · Cited by 38
Self-citationDecoding Parkinson’s Disease Pathogenesis: The Role of Deregulated mRNA Translation
Martin, I. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150738 · Cited by 23
Metadata
- Authors
- Luzon-Toro, B., de la Torre, E. R., Delgado, A., Perez-Tur, J., & Hilfiker, S.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-25
- Volume
- 16
- Issue
- 17
- Pages
- 2031-2039
- ISSN
- 0964-6906
- 1460-2083
- Cited by
- 122
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review